MINAPHARM Pharmaceuticals (EGX:MIPH)
Egypt · Delayed Price · Currency is EGP 807.87
+5.16 (0.64%)
At close: Sep 14, 2026
MINAPHARM Pharmaceuticals Ratios and Metrics
Market cap in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 9,517 | 4,114 | 1,796 | 2,408 | 1,822 | 1,303 | |
Market Cap Growth | 221.14% | 129.01% | -25.41% | 32.19% | 39.82% | 32.02% |
Enterprise Value | 10,973 | 5,812 | 4,355 | 4,087 | 2,625 | 1,448 |
Last Close Price | 807.87 | 348.09 | 160.15 | 212.94 | 143.14 | 100.38 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 28.07 | 621.84 | 14.01 | - | 3.09 | 2.91 |
PS Ratio | 1.43 | 0.64 | 0.32 | 0.62 | 0.50 | 0.43 |
PB Ratio | 1.39 | 0.65 | 0.42 | 0.69 | 0.60 | 0.67 |
P/TBV Ratio | 1.60 | 0.75 | 0.50 | 0.80 | 0.70 | 0.81 |
P/OCF Ratio | 29.44 | 8.85 | 8.11 | 23.53 | 3.24 | 6.29 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.65 | 0.90 | 0.78 | 1.05 | 0.73 | 0.48 |
EV/EBITDA Ratio | 7.66 | 4.31 | 3.72 | 7.63 | 2.42 | 1.73 |
EV/EBIT Ratio | 10.78 | 5.71 | 4.66 | 10.91 | 2.72 | 1.92 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.73 | 0.71 | 1.30 | 1.08 | 0.80 | 0.64 |
Debt / EBITDA Ratio | 3.47 | 3.25 | 4.58 | 6.71 | 2.22 | 1.49 |
Net Debt / Equity Ratio | 0.19 | 0.18 | 0.63 | 0.54 | 0.24 | 0.14 |
Net Debt / EBITDA Ratio | 0.96 | 0.82 | 2.29 | 3.52 | 0.68 | 0.32 |
Net Debt / FCF Ratio | -2.48 | -3.44 | -3.85 | -1.46 | -1.24 | -1.47 |
Asset Turnover | 0.50 | 0.51 | 0.54 | 0.50 | 0.66 | 0.79 |
Inventory Turnover | 2.92 | 3.03 | 3.21 | 2.79 | 2.82 | 2.90 |
Quick Ratio | 0.91 | 0.82 | 0.75 | 0.70 | 0.87 | 0.92 |
Current Ratio | 1.43 | 1.30 | 1.21 | 1.15 | 1.46 | 1.61 |
Return on Equity (ROE) | 6.41% | 0.89% | 4.13% | 0.68% | 25.32% | 26.86% |
Return on Assets (ROA) | 4.74% | 5.06% | 5.63% | 3.02% | 11.05% | 12.42% |
Return on Invested Capital (ROIC) | 8.96% | 3.11% | 8.69% | 5.52% | 23.09% | 28.67% |
Return on Capital Employed (ROCE) | 10.80% | 12.20% | 12.80% | 7.20% | 22.40% | 28.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.35% | 0.98% | 8.74% | -1.33% | 33.63% | 35.79% |
FCF Yield | -5.63% | -7.85% | -38.82% | -53.66% | -32.84% | -13.86% |
Dividend Yield | 0.31% | - | 1.56% | 0.78% | 1.96% | 2.91% |
Payout Ratio | 17.23% | 149.97% | 25.57% | - | 9.43% | 10.68% |
Buyback Yield / Dilution | - | - | - | 3.57% | 6.67% | - |
Total Shareholder Return | 0.31% | - | 1.56% | 4.35% | 8.62% | 2.91% |